AHR and neoplasm: Consistent with this concept, recent work has demonstrated metabolism-directed strategies to overcome EGFR-TKI resistance, including inhibition of BCAT1/BCAA metabolism and disruption of kynurenine–AHR signaling in the tumor microenvironment [39], [40].